Since the completion of the Human Genome Project in 2003, there has been huge growth in the utilisation of genomics, but how can partnerships in this area be used to improve patient experience?
This is the topic covered by our CEO Simon Davis in the summer edition of ‘Innovations in Pharmaceutical Technology’. During an in-depth interview, Simon explains the benefits of public/private partnerships, and why they are so important in driving innovation and value to healthcare providers and their patients. Please see an excerpt of the article below.
IPT: What are the key benefits that public/private partnerships can bring in genomics to research and innovation and access to resources and expertise?
Simon Davis: Public-private partnerships play a crucial role in advancing research and innovation, bringing together stakeholders from all sectors, including government, academia, industry and patient advocacy groups. Some of the benefits of these partnerships include addressing bottlenecks in research and development by aligning the partners’ efforts, providing a means for various NHS Trusts to access new technologies, speeding up national commissioning decisions, and supporting faster access for patients. The evidence generated through adopting novel genomics technologies on a pilot supports a downstream value assessment and evidence-based decision-making for adopting new tests. Additionally, partnerships can provide a cornerstone for establishing new infrastructure within the NHS, with companies able to provide the capacity and capabilities that would be far too resource-intensive for individual NHS Trusts and laboratories to develop individually.
Regarding research, partnerships can drive the establishment of regulatory standards, ensuring research adheres to quality and safety guidelines and helping reduce costs by sharing resources and expertise across organisations, leading to more efficient research. They also allow for economies of scale – by pooling resources, such as data, infrastructure and funding, researchers can achieve more significant impact and accelerate their discoveries. Finally, they can facilitate faster progress through combined expertise, enabling researchers to collaborate on complex health challenges, leading to medical breakthroughs for patients.
Read the article in full: Innovations in Pharmaceutical Technology, Summer 2024 © Samedan Ltd.
Collaborating with Informed Genomics
At Informed Genomics, we are committed to creating and developing partnerships across the public and private sectors to help deliver healthcare services for patients. By fostering these innovative relationships, we enable more patients to access genomic testing, which offers such huge benefits to patients when it comes to early disease detection, as well as identifying rare diseases, optimising cancer treatments and in prenatal and neonatal screening programmes.
Please see below two examples of these collaborations.
- Read about our work with the NHS as the only private laboratory to support the NHS Jewish BRCA Testing Programme, part of the NHS’ major drive to detect cancer early when it is easier to treat.
- Discover how Informed Genomics collaborated with Bupa insurance to make its pioneering GALEAS™ Bladder cancer testing service available to the insurer’s customers.
